MedTrace Logo

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

NCT04524169 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-08-26

No results posted yet for this study

Summary

Osteoporotic pain is the most common clinical symptom in elderly patients. The course of pain is prolonged and the effect of clinical treatment is limited. This study will observe the therapeutic effect of thymosin alpha 1 on elderly patient with osteoporotic pain and explore its immunotherapy mechanism.

Conditions

  • Osteoporotic Pain

Interventions

DRUG

Thymosin Alpha1

Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Weifeng Yu · Department of Anesthesiology, Renji Hospital, School of Medicine, SJTU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04524169 on ClinicalTrials.gov